Citations

Clear

1575 citation(s) found for "Im, Gene".

Relationship Between a Weighted Multi‐Gene Algorithm and Blood Pressure Control in Hypertension
Phelps, Pamela, Snyder, Eric M., Walla, Danielle, Simmons, Jerad, Bulock, Emma K, Ayres, Audrie, Akre, Monica K. , Sprissler, Ryan , Olson, Thomas P. , Ross, Jennifer

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 33 | Issue: S1 | Pages: No page available

10.1096/fasebj.2019.33.1_supplement.819.6 Get It

Background Hypertension (HTN) has a strong heritable component and the effectiveness of the treatment for HTN has been shown to be influenced by monogenic guidance. Each of the common HTN pharmacotherapies is ~50% effective in the population and layering blood pressure (BP) medications increases side effects and decreases medication adherence. HTN is a complex disease with primary interactions between the heart, vasculature, and kidney. Known and common genetic variants of each these organs have well‐described mechanisms. Despite the established bell‐curve response to treatment, the complexity of HTN, and functional variants of the major organ systems in HTN: no guidance, to date, utilizes a multi‐gene approach to guide BP therapy. Purpose To assess the association between a weighted multi‐gene algorithm and BP control in patients with HTN. Methods Non‐smokers with a family history of HTN were included in the analysis (n=384; age=61.0±0.9, 11% non‐white). 17 genotypes (ADRB1(2 SNPs), ADRB2 (2SNPs), CYP2D6, WNK (3SNPs), SLC12A3, SCNN1A, alpha‐adducin, renin, angiotensin (3 SNPs), ACE, and the angiotensin receptor) were weighted according to previous effect size in the literature (ΔBP when on the target therapy vs. not) as well as the number of peer‐reviewed papers of quality supporting each functional variant. After weighting, each genotype was entered into an algorithm that assessed pairing (e.g. homozygosity of functional ADRB1 is responsive to β‐blockade, heterozygosity is less responsive, and homozygosity of non‐functional is least responsive) within and between organ systems to predict the pharmacotherapy with greatest impact for each individual patient. Each pharmacotherapy was ranked from 1–4 as most to least likely to respond based on the algorithmic assessment of individual patient's genotypes. Three‐years of data was assessed at six‐month intervals for BP and medication history. Current and past pharmacotherapies were also assessed via chart review. Results There was no difference in initial BP at diagnosis between groups matching the top drug recommendation using the multi‐gene weighted algorithm (n=92) vs. those who did not match (n=292). However, from diagnosis to nadir, patients who matched the primary recommendation had a significantly greater drop in BP when compared to patients who did not (ΔSBP= −39.2±2.4 vs. −32.1±1.3mmHg , ΔDBP= −19.4±1.1 vs. −14.0±1.3mmHg , ΔMAP= −24.4±2.1 vs. −19.0±1.2mmHg, respectively, p<0.05 for SBP and DBP). Further, the difference between diagnosis to current 1yr. average BP was lower in the group that matched the top recommendation (ΔSBP= −33.2±2.3 vs. −27.4±1.2mmHg, ΔDBP=−14.8±1.1 vs. −11.5±1.2, ΔMAP= −21.2±2.3 vs. −15.6±1.8, respectively, p<0.05 for SBP and MAP). Conclusions These data suggest an association between a weighted multi‐gene algorithm on the BP response to pharmacotherapy. This magnitude of difference has previously been shown to be associated with a significant reduction in heart attack and stroke risk. Support or Funding Information Geneticure, Inc. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Altered Pattern of Gene Expression in Thoracic Aortic Aneurysms in Patients with Trileaflet and Bileaflet Aortic Valve: A Pilot Study Using Affymetrix Gene Chips
Majumdar, Ramanath, Sami, Takieddine, Yagubyan, Marineh, Sarkar, Gobinda , Bolander, Mark E., Sundt, Thoralf M.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 5 | Pages: No page available

10.1096/fasebj.20.5.a1074 Get It

OBJECTIVE A bileaflet aortic valve (BAV) occurs in 1–2% of the population, making it the most common cardiovascular malformation. Patients with BAV have increased risk of thoracic ascending aortic aneurysm (TAA) and dissection compared to those with trileaflet aortic valves (TAV). We have evaluated the gene expression profile of the aorta of patients with BAV and TAV with TAA. METHODS Segment of aneurysmal tissue was collected from 12 patients with BAV (age 43–68) and 19 patients with TAV (age 37–79). RNA was extracted using the Invitrogen RNA extraction Kit. RNA that was of adequate quality by the Agilent Bioanalyzer was used in the Affymetrix protocol for the U133A gene chips probing for over 16,000 genes on each chip. Real‐time RT‐PCR was used to confirm the microarray results for a subset of genes. RESULTS Data filtering (using two different statistical methods) identified significant differences in gene expression between the BAV and TAV groups. The real time RT‐PCR independently confirmed that the expression levels of osteopontin and tenascin were consistently increased in TAA with TAV. CONCLUSIONS The results indicate that many genes are involved in a complicated manner in the pathogenesis of TAA. This study also demonstrates two basic gene expression profiles in the TAA, one characteristic of patients with BAV and the other of those with TAV. Variations in the molecular mechanisms underlying different types of TAA warrant further investigation. (This work was supported by an SS‐50 award to Dr. Thoralf Sundt from the Department of Surgery, Mayo Clinic)
The Impact of Long‐Term Physical Activity on Age‐Related Changes in Protein and Gene Expression
Short, Daniel K., Asmann, Yan W. , Raghavakaimal, Sreekumar, Bigelow, Maureen L., Lanza, Ian R. , Short, Kevin R. , Joyner, Michael J. , Nair, K. Sreekumaran

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.1163.21 Get It

Age‐related mitochondrial dysfunction is paralleled by reductions in gene transcripts and expression of proteins involved in cellular ATP production. Short‐term endurance exercise has been shown to enhance muscle protein synthesis in the elderly. We determined the impact of long‐term endurance exercise on gene expression and protein abundance of numerous proteins involved in cellular energetics. Vastus lateralis tissue was biopsied from 11 young sedentary (YS), 10 old sedentary (OS), 11 young trained (YT), and 11 old trained (OT) subjects. Trained subjects vigorously exercised ¡Ý 1 hr/d, ¡Ý five d/wk for ¡Ý 4 years. Large‐scale measurement of relative protein abundance was performed using isobaric tags for relative and absolute quantitation (iTRAQ) reagents and tandem mass spectrometry. Gene transcript levels were measured by high‐density oligonucleotide microarrays. Ingenuity Pathway Analysis was used to determine canonical pathways that were altered by age. Of the 33 proteins involved in cellular ATP production 27 were less abundant in OS vs. YS, while only 4 of these proteins were less abundant in OT vs. YT. Genes involved in glycolysis and oxidative phosphorylation were underexpressed in OS vs. YS, with no effects of age in OT vs. YT. CONCLUSIONS: Long‐term vigorous endurance exercise ameliorates the detrimental effects of old age on muscle gene and protein expression in humans.
Heart – Kidney Connection: Myocardial Infarction Induces Widespread Changes in Renal Cortical and Medullary Gene Expression together with Cortical and Medullary Fibrosis
Martín, Fernando L., Huntley, Brenda K., Harders, Gerald E., Sandberg, Sharon M., Heublein, Denise M., Burnett, John C.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.970.34 Get It

Studies in human myocardial infarction (MI) suggest that even in the absence of heart failure (HF) alterations in renal function may occur and contribute to poor outcomes. We hypothesized that even without preexisting renal disease, renal functional, structural and molecular changes would be present following MI. Wistar rats were used, Sham(S;n=10) and MI(n=9). 3 weeks after MI, GFR was determined by inulin clearance. Blood was obtained for PRA and aldosterone. Cardiac function was assessed by echo. Genomewide microarray analysis was performed on kidney cortex (KC) and medulla (KM) (Affymetrix). EF decreased after MI (S:63±2, MI:43±6%, p<0.01) and LVEDd increased. PRA, aldosterone and blood pressure (BP) did not change. There was no HF as Na and water excretion was maintained. GFR tended to decrease. Pic Red staining in the KC and KM after MI showed greater fibrosis (KC S:1±0.2, MI:3±0.6%, p<0.001 and KM S:1±0.2, MI:19±6%, p<0.005). Microarray analysis showed that 303 genes changed in KM and 407 genes in KC after MI (1.5 fold, P<0.05) related to structure morphogenesis and metabolic processes(Z value>2). We conclude that experimental MI results in renal structural remodeling characterized by cortical and medullary fibrosis with a mild reduction in GFR and extensive modulation of molecular pathways related to renal growth and morphogenesis underscoring a heart‐kidney connection after MI.
Gene‐by‐Gene Interactions Between Phenylethanolamine N‐Methyltransferase and the Beta‐2 Adrenergic Receptor and the Ventricular Response to Exercise
Snyder, Eric M., Ji, Yuan , Weinshilboum, Richard M. , Johnson, Bruce D., Joyner, Michael J. , Turner, Stephen T. , Weinshilboum, Richard M.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.966.1 Get It

Epinephrine is a sympathomimetic which is derived from phenylalanine and tyrosine. The final step of epinephrine synthesis, the conversion from norepinephrine, relies on phenylethanolamine N‐methyltransferase (PNMT). The beta‐2 adrenergic receptor (ADRB2) binds to epinephrine and has several common functional polymorphisms including a Glycine (Gly) for Arginine (Arg) substitution at amino acid 16. We assessed the effect of the gene‐to‐gene interaction of these proteins on the ventricular response to exercise in healthy humans (n=69, age=29±6yrs, ht=174±10cm, wt=71±13kg). We found that within the 2*1 haplotype of the 5′FR, which has previously demonstrated greater epinephrine synthesis compared to 2*7 haplotype, the Arg16 genotype demonstrates lower stroke volume (SV) than the Gly16 genotype despite similar epinephrine levels and synthesis rates (Arg16= 75±5, Gly16=89±6ml/beat). Similarly, within the 2*7 haplotype of the 5′FR, which has demonstrated attenuated epinephrine synthesis compared to 2*1, the Arg16 genotype demonstrates a smaller SV than the Gly16 genotype (Arg16= 59±3, Gly16=78±6ml/beat). Additionally, the Arg16 and Gly16 subjects within the 2*1 haplotype of PNMT have greater stroke volume than their ADRB2 counterparts of the 2*7 haplotype of PNMT. These data demonstrate an interaction between the genes that encode PNMT and ADRB2 on the ventricular response to exercise.
Identification of a New Gene in the Mouse MHC Class II Gene Cluster
David, Chella S., Jensen, Peter E. , Chen, Lili , He, Xiao

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 22 | Issue: S1 | Pages: No page available

10.1096/fasebj.22.1_supplement.849.15 Get It

MHC Class II molecules are essential in antigen presentation and selection of the CD4+ T cell repertoire. They are mainly expressed on professional Antigen Presenting Cells (APC), i.e. B lymphocytes, dendritic cells and macrophages. Activated human T lymphocytes also express MHC Class II but MHC Class II expression is not detected on activated mouse T cells. HLA‐DR3 can be expressed as a transgene on CD4+ T cells in complete MHC Class II knock‐out (AEo) mice, but not in I‐Ab knock‐out (Abo) mice, suggesting that a gene, which could modify the expression of HLA‐DR3, might exist between I‐A and I‐E. Expression sequence tag (EST) databases were searched using the flank regions between I‐A and I‐E and a new potential gene was identified. No similar sequence was found in the human genome database. Expression in multiple mouse tissues, but not in human cell lines, was verified by RT‐PCR. However, this gene was found to be expressed in B6 mouse B cells and two mouse B cell lines, but not in T cells, indicating that it might not be related to the expression of HLA‐DR3. Transduction of this gene into the LG2 cell line had no effect on MHC II expression. In summary, we report the discovery of a new gene between the I‐Aa and I‐Eb1 region in C57BL/6 mice and its function remains unknown. (Supported by NIH‐AI30554)
Immunohistochemical expression of pituitary tumor transforming gene in pituitary adenomas: clinico‐pathological variables
Salehi, Fateme , Manoranjan, Branavan , Scheithauer, Bernd W., Lloyd, Ricardo V., Kalman, Kovacs, Cusimano, Michael D.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.925.8 Get It

Pituitary tumor transforming gene (PTTG) was initially found to be overexpressed in GH4 rat pituitary adenomas (PA). PTTG overexpression has been correlated with patient survival, tumor grade, and/or invasiveness in several tumors including those of thyroid, breast, lung, and colon. Studies of PTTG as a prognostic indicator in PAs are limited and show conflicting results. We investigated PTTG immunostaining in 79 PAs of different subtypes (growth hormone (GH), 12; prolactin (PRL), 6, adrenocorticotropic hormone (ACTH), 11, gonadotroph, 21; null cell, 29) in relation to clinico‐pathological variables including patient age and sex, as well as tumor size, and invasiveness. The streptavidin‐biotin‐peroxidase method was used, with a monoclonal PTTG antibody (Abcam, Cambridge, UK). PTTG expression was found to be cytoplasmic in all PAs, with highest levels being present in GH adenomas and lowest in the PRL ones. No correlation was found with patient age, sex, tumor size or invasiveness. Thus, it appears that PTTG cannot serve as a prognostic marker in patients with PAs. PTTG has been implicated in several tumorigenic processes including angiogenesis, DNA damage repair and invasiveness. PTTG overexpression in PA warrants further research into its role in PA initiation and progression.
Copy number of human SULT1A1 gene among newly menopausal Caucasion women
Moyer, Ann M. , Weinshilboum, Richard M. , Miller, Virginia M. , Weinshilboum, Richard M.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 23 | Issue: S1 | Pages: No page available

10.1096/fasebj.23.1_supplement.750.7 Get It

There is large variation in response to menopausal hormone treatments among women and it remains unclear as to what genetic factors might increase risk of breast cancer in women using such treatments to relieve symptoms of menopause. SULT1A1 is a ubiquitous enzyme involved in the metabolism of steroid hormones including estrogen. A number of polymorphisms in the gene for this enzyme are associated with various cancer risks and the activity level of the enzyme is correlated closely with variation in copy number of the gene. This pilot study evaluated SNP variation and copy number of SULT1A1 in a subset of women (n=156) being screened for the Kronos Early Estrogen Prevention Study (KEEPS). All participants gave written informed consent. DNA prepared from blood was genotyped for SULT1A1 copy number, rs3760091 and rs750155 from the promoter region of SULT1A1, and rs9282861 from the coding region (SULT1A1*2 variant). In this cohort, 5.2% had 1 copy of SULT1A1, 65.2% had 2 copies, 23.9% had 3 copies, and 5.8% had 4 copies. Previously reports of the allele frequency for the three SNPs did not take into account gene copy number. When copy number was taken into account, allele frequency was significantly different, a fact that will have to be taken into account in future genotype‐phenotype correlations. (Supported by grants from the Kronos Longevity Research Institute, NIH HL90639, RR24150 and GM61388.)
Effect of leucine on mitochondrial gene expressions, enzyme activities, and ATP production capacities in liver cells
Asmann, Yan W. , Coenen-Schimke, Jill M., Nair, K. Sreekumaran

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 20 | Issue: 4 | Pages: No page available

10.1096/fasebj.20.4.a8-c Get It

Leucine (Leu) is the most potent branched‐chain amino acid that selectively enhances protein synthesis via intracellular signaling pathways. Since protein synthesis is an energy consuming process, we hypothesized that Leu may enhance mitochondrial biogenesis and functions. We determined the effect of Leu at mitochondrial mRNA levels, enzyme activities, and ATP production rate (MAPR) in cultured human liver cell line THLE‐3. Cells were pre‐incubated in a low‐Leu (0.1mM), serum‐free media for 24 hours and gene transcript profiles were measured using Affymetrix HG‐U133A GeneChips at 0, 30, 60, 120 and 480 minutes after increasing the Leu concentrations from to 2.0 mM. Thirty mitochondrial gene transcripts, both mitochondrial DNA and nuclear‐encoded, were significantly increased at various time points with treatment of higher concentrations of Leu. The mRNA levels of 6 mitochondrial genes including two ATP synthase, cytochrome P450, cytochrome C oxidase III, and NADH dehydrogenase 4 were confirmed by real‐time PCR measurements. Western blot analysis showed that 8 hours of high concentrations of Leu increased protein levels of key mitochondrial proteins, citrate synthase and cytochrome c oxidase I, by 42% and 20% respectively. In addition, the enzyme activity of citrate synthase was significantly increased by 25%, and MAPR by 30–40% using various substrates after 8 hours of high Leu. In conclusion, Leu stimulated mitochondrial biogenesis and oxidative phosphorylation in liver cells. This work is supported by NIH grants T32 DK7352, and RO1 DK41972.
Abstract 470: Computational Identification of NKX2-5 Binding Sites and Downstream Gene Targets Using Transcription Factor Motif and Human Heart-specific Experimental Data
Tan, Nicholas Y. , Chung, Mina K. , Smith, Jonathan D. , Wagoner, David R. Van , Barnard, John

Mayo Clinic

Circulation Research | June 21, 2021 | Volume: 119 | Issue: suppl_1 | Pages: No page available

10.1161/res.119.suppl_1.470 Get It

Background: While NKX2-5 plays pivotal roles in human cardiac development and disease, no ChIP-Seq studies of NKX2-5 in human cardiac tissues currently exist, resulting in an incomplete understanding of its direct gene targets. Modern computational methods which identify binding sites using transcription factor motif and tissue-specific experimental data can help to fill this knowledge gap. Objective: To use computational methods to identify likely NKX2-5 binding sites and downstream gene targets using human heart-specific experimental data. Methods: Human cardiomyocyte DNAse hypersensitivity data (2 replicates) were downloaded from the Encyclopedia of DNA Elements (ENCODE) database. The position weight matrix (PWM) representing the transcription factor motif of NKX2-5 was obtained from JASPAR. We applied the Protein Interaction Quantification (PIQ) algorithm to detect NKX2-5 binding sites using the PWM and DNAse hypersensitivity data as inputs. RNA-Seq data from 108 human heart-specific samples (atrial appendages and left ventricles) were downloaded from the Genotype-Tissue Expression (GTEx) database. Protein-coding genes significantly expressed in the heart (RPKM <= 1 based on the GTEx RNA-Seq data) that were within 100kb of the predicted binding sites were then identified. Pathway analysis of these genes was performed using Ingenuity Pathway Analysis (IPA). Results: 1283 binding sites for NKX2-5 were discovered by PIQ. Of 12698 protein-coding, heart-expressed genes, 625 were within 100kb of these binding sites. The identified genes were highly enriched in physiologic categories like “Vasculogenesis” and “Development of Cardiovascular Tissue” (p = 2.36x10-9 and 2.31x10-8 respectively). Notable genes included: cardiac transcription factors (MEF2A, TBX20); growth factors (TGFB2, BMP2); muscle and ion channel function (ACTA2, BIN1), and; calcium signaling (CALM2, CAMK2D). Conclusion: By using computational analyses of transcription factor motif and human heart-specific experimental data, we have identified candidate downstream targets of NKX2-5. Future work will include validation studies in an external cohort and analysis of associations between these candidate genes and cardiac disease.